Articles tagged with 'Export-IR' | Bayer

New issue of two tranches with a non-call period of 5.25 and 8.25 years, respectively, combined with a tender offer for two of Bayer’s existing hybrid bonds

Leverkusen, September 19, 2023 – Dr. Jost Reinhard will take over as head of Bayer AG’s Investor Relations department effective October 1, 2023. The 51-year-old is currently responsible for Bayer’s Cell and Gene Therapy unit in the United States. Rei...

Investigational VVD-130037 is highly specific, potent Kelch-like ECH Associated Protein 1 (KEAP1) activator developed for treatment of advanced solid tumors / Major milestone for Vividion’s chemoproteomics innovative technology platform / First-in-cl...

New agreement will focus on CRISPR applications for Bayer’s Preceon™ Smart Corn System / Collaboration builds on successful initial gene-editing partnership between the two companies that resulted in 27 novel traits being transferred into Bayer’s tes...

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year. / At one-year, exploratory clinical endpoints improved overall, with...

Three new investigator-sponsored collaborative studies are funded by Bayer and will evaluate the efficacy and safety of finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist (MRA), in approximately 9,300 heart failure (HF) pati...

Leverkusen, August 21, 2023 – The Supervisory Board of Bayer AG has unanimously appointed Heike Prinz to Bayer’s Board of Management effective September 1, 2023. She will become the company’s Chief Talent Officer and Labor Director. This follows the ...

Group sales fall by 8.2 percent (Fx & portfolio adj.) to 11.044 billion euros / EBITDA before special items: 2.527 billion euros (minus 24.5 percent) / Crop Science business down significantly, mainly due to sharp decline in glyphosate volumes and pr...

Leverkusen, July 24, 2023 – The Bayer Group adjusted its full-year outlook for 2023 downward on Monday, mainly due to a significant further decline in sales of glyphosate-based products.For full-year 2023, Bayer now anticipates sales of between 48.5 ...

Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to EyleaTM (aflibercept 2 mg) at fixed 8-weekly dosing over two years / Patients assigned to a 16-week dosing regimen at baseline rec...

R&D strategy poised to translate higher quality and productivity in Bayer’s innovation model into long-term growth in four key focus areas with high unmet patient needs / Shifting to breakthrough innovations based on new scientific approaches, platfo...

Investigational Bemdaneprocel (BRT-DA01) was well tolerated with no major safety issues in all 12 patients through one year / Assessment of secondary endpoints demonstrates feasibility of transplantation and evidence of cell survival and engraftment ...

Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) / CKD affects up to 40% of people with T1D / A quarte...

Expectation to tap into more than 100 billion euros of value in accessible and ag-adjacent markets  / Unparalleled pipeline with estimated peak sales potential of more than 30 billion euros to promote regenerative agricultural practices and enable fa...

Issuance consisted of three tranches with maturities between 3.25 and 10 years and was substantially oversubscribed

The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries / Asundexian is being evaluated as a potential improved treatment option in st...

Group sales stable at 14.389 billion euros (Fx & portfolio adj. minus 1.1 percent)o   Accelerated normalization in glyphosate business – good price dynamics in other Crop Science unitso   New Pharmaceuticals products deliver strong growth – headwinds...

Generating 1,400 GWh annually, Idaho Renewable Energy Agreement Underscores Bayer's Global Commitment to Sustainability and Rural Communities

Substantial sales and earnings growth in 2022 / Dividend of 2.40 euros per share proposed – up 20 percent / Baumann to retire at the end of May – Bill Anderson designated as his successor

Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline / Fifth major cl...

Holistic approach to improve water use and quality across the entire value chain and contribute to an impactful change / Integration of water stewardship in business and investment decisions / Shaping a water-resilient agriculture system with key con...

Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer / Additional indication based on data from the pivotal Phase III ARASENS trial ...

Ready-to-use AgPowered Services from Bayer running on the new Microsoft Azure Data Manager for Agriculture / Readymade capabilities and robust digital infrastructure allow innovators to focus on differentiated value / Companies, farmers and consumers...

European Commission granted approval of Nubeqa™ (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Approval is based on Phase III ARASENS trial data...

Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PUL...

Group sales increase 8.7 percent (Fx & portfolio adj.) to 50.739 billion euros / EBITDA before special items rises 20.9 percent to 13.513 billion euros, largely driven by exceptionally strong performance at Crop Science / Pharmaceuticals increases sa...

Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer / New approval based on data from the pivotal Phase III ARASENS trial 

European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (...

Leverkusen, February 8, 2023 – The Supervisory Board of Bayer AG has appointed Bill Anderson to become CEO of Bayer, effective June 1, 2023. He will join Bayer as a member of the Board of Management on April 1, 2023. Bill Anderson was elected unanimo...

Filing for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of clinical trials, PULSAR and PHOTON / In both trials, aflibercept 8 mg demonstrated unprecedented...